NLS Pharmaceutics announces expected compliance with Nasdaq listing rules

Private Placement and Debt Agreement: NLS Pharmaceutics completed a private placement of 806,452 common shares and warrants for $3.2 million, along with a debt purchase agreement to issue convertible preferred shares in exchange for $4 million in debt relief.

Compliance with Nasdaq Requirements: The company believes it has regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements, as its shares have traded above $1.00 for ten consecutive days and it meets the $2.5 million equity threshold.